Daily Stock Analysis, BSX, Boston Scientific Corp, priceseries

Boston Scientific Corp. Daily Stock Analysis
Stock Information
Open
31.95
Close
32.23
High
32.53
Low
31.87
Previous Close
31.92
Daily Price Gain
0.31
YTD High
37.30
YTD High Date
Jun 11, 2018
YTD Low
24.84
YTD Low Date
Jan 2, 2018
YTD Price Change
6.95
YTD Gain
27.49%
52 Week High
37.30
52 Week High Date
Jun 11, 2018
52 Week Low
24.54
52 Week Low Date
Dec 6, 2017
52 Week Price Change
4.32
52 Week Gain
15.48%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
21.88
Jan 26. 2017
23.52
16 Trading Days
7.49%
Link
LONG
Apr 19. 2017
24.81
May 12. 2017
26.30
17 Trading Days
5.99%
Link
Company Information
Stock Symbol
BSX
Exchange
NYSE
Company URL
http://www.bostonscientific.com
Company Phone
508-683-4000
CEO
Michael F. Mahoney
Headquarters
Massachusetts
Business Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA 01752-1234
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0000885725
About

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. Its products and technologies are used to diagnose or treat medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health and chronic pain conditions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral arterial disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.